Couverture de From Breakthrough to Blockbuster

From Breakthrough to Blockbuster

The Business of Biotechnology

Aperçu

Bénéficiez gratuitement de Standard pendant 30 jours

5,99 €/mois après la période d’essai. Annulation possible à tout moment
Essayez pour 0,00 €
Plus d'options d'achat

From Breakthrough to Blockbuster

De : Donald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos
Lu par : Chris Andrew Ciulla
Essayez pour 0,00 €

Renouvellement automatique à 5,99 € mois après 30 jours. Annulation possible chaque mois.

Acheter pour 15,48 €

Acheter pour 15,48 €

À propos de ce contenu audio

Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources.

Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs.

From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.

©2022 Oxford University Press (P)2022 Ascent Audio
Développement commercial et entrepreneuriat Médecine et secteur des soins de santé Science
Aucun commentaire pour le moment